A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05298592
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986406 — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • Carboplatin — DRUG
    Specified dose on specified days
  • Pemetrexed — DRUG
    Specified dose on specified days
  • Paclitaxel — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with advanced tumors.

Key Dates

Start date
Mar 31, 2022
Status verified
Sep 2024
Primary completion
Aug 16, 2024
Completion
Aug 16, 2024

Study Design

Enrollment
77 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1A: BMS-986406 (Monotherapy Dose Escalation)
  • Experimental: Part 1B: BMS-986406 + Nivolumab (Combination Dose Escalation)
  • Experimental: Part 1C: BMS-986406 + Nivolumab (Indication-Specific Dose Expansion)
  • Experimental: Part 2: BMS-986406 + Nivolumab (Expansion Cohorts)
  • Experimental: Part 1D: BMS-986406 + Nivolumab + Carboplatin with Pemetrexed or Paclitaxel

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 100 days ]

Locations (9)

FacilityCityStateZIPSite coordinators
Local Institution - 0021BirminghamAlabama35213-
University California San Diego Moores Cancer CenterLa JollaCalifornia92093-
The Angeles Clinic and Research Institute, A Cedars-Sinai AffiliateLos AngelesCalifornia90025-
UCLA HealthLos AngelesCalifornia90404-
Local Institution - 0001HackensackNew Jersey07601-
Carolina BioOncology Institute, PLLCHuntersvilleNorth Carolina28078-
Sanford Cancer CenterSioux FallsSouth Dakota57104-
Mary Crowley Cancer Research - Medical City HospitalDallasTexas75230-
Local Institution - 0006RichmondVirginia23298-

Find similar trials in Birmingham, AL

By research site
Local Institution - 0021· Birmingham, ALUniversity California San Diego Moores Cancer Center· La Jolla, CAThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate· Los Angeles, CAUCLA Health· Los Angeles, CALocal Institution - 0001· Hackensack, NJCarolina BioOncology Institute, PLLC· Huntersville, NC

Related Studies